The medical laboratory science (MLS) profession is in need for published molecular diagnostics competency-based standards and curriculum. To assess their expectations of new MLS graduates, professionals performing and supervising performance of clinical molecular assays were surveyed to rate the importance of relevant cognitive and psychomotor learning objectives. A modified, asynchronous, iterative online Delphi process was utilized for assessment of consensus on the importance of the objectives. The survey was delivered through online REDCap application. Program directors of 221 MLS programs accredited by the National Accrediting Agency for Clinical Laboratory Science (NAACLS) were asked to forward the first Delphi survey to target participants at their affiliated clinical sites. Ninety-four experts submitted complete surveys, including 88 who provided email addresses, indicating agreement to participate in future Delphi rounds. Most of the participants were certified by ASCP or NCA (81.9%), had over 10 years of laboratory experience (76.6%), and worked in a hospital setting (43.6%). The reliability of the surveys, assessed using Cronbach’s alpha, was 0.96 and 0.97. In the second survey, the objectives assigned low importance by the majority were removed; and others, assigned high importance were expanded. Respondents were given the opportunity to confirm or change their opinion on the objectives after reviewing quantitative results and narrative comments collected in the preceding survey. Upon completion of the Delphi process, 25 essential items were identified as necessary for inclusion in the entry-level MLS curriculum. These concepts and objectives focused on basic molecular biology principles and general molecular laboratory operations, including practical knowledge of techniques designed to maintain specimen integrity and intense theoretical background of the polymerase chain reaction, as well as comprehension of the principles of laboratory assays designed for pathogens most commonly tested for using molecular methods. In this study, the investigator also provided information on the preferred number of contact hours devoted to each group of the identified essential items. The goal of creating the list of essential concepts and objectives was to share it with MLS educators, the NAACLS and the provider of MLS certification exam, the American Society for Clinical Pathology Board of Certification (ASCP-BOC), to contribute to the existing exam content guidelines.

<p>Objective: The aim of this study was to evaluate a new underfill-function in a POCT-instrument from HemoCue AB (Ängelholm, Sweden). The instrument is in use today among diabetes patients for self-monitoring blood glucose (SMBG). The new function is supposed to guarantee that measuring only will be performed on a sufficient sample volume to assure that the correct glucose value is received.</p><p>Methods and results: Blood samples (whole blood) from 12 patients were analysed with the instrument. Measuring were performed using different volumes in the cuvette. Full cuvette, 3µL, 2µL, 1µL and a measuring on an empty cuvette. The instrument performed measurements on all volumes added to the cuvette except for the empty cuvette. The less sample volume that was used the lower glucose values were reported by the instrument.</p><p>Conclusions: The new under fill-function did not work satisfactory. If such function would be more reliable it would be beneficial for the patient controlling hers/his bloodglucose provided that the testing procedure is being correctly done. This is very important because the results are often used to treat the patient.</p>

<p>Abstract</p><p>Crimean-Congo Hemorrhagic Fever virus (CCHF) and Lassa virus are giving sources illness to humans. In addition to zoonotic transmission, CCHF and Lassa virus can spread from person to person. After a short incubation period, CCHF and Lassa virus infections are characterized by a sudden onset of high fever, chills, headache and cough just like flu. Even some people are vomiting and have diarrhoea. After a few days of illness hemorrhagic manifestations occur. Treatment options for CCHF and Lassa viruses are limited, and there is no vaccine available for use in humans. The purpose of the present study was to produce recombinant nucleocapsid protein of Lassavirus and CCHF virus including an aminoterminal His-tag by a Semliki Forest Virus Replicon (pSFV 4.2). The recombinant proteins are planned to be used in future development of diagnostic methods.</p>

Objective: The aim of this study was to evaluate a new underfill-function in a POCT-instrument from HemoCue AB (Ängelholm, Sweden). The instrument is in use today among diabetes patients for self-monitoring blood glucose (SMBG). The new function is supposed to guarantee that measuring only will be performed on a sufficient sample volume to assure that the correct glucose value is received. Methods and results: Blood samples (whole blood) from 12 patients were analysed with the instrument. Measuring were performed using different volumes in the cuvette. Full cuvette, 3µL, 2µL, 1µL and a measuring on an empty cuvette. The instrument performed measurements on all volumes added to the cuvette except for the empty cuvette. The less sample volume that was used the lower glucose values were reported by the instrument. Conclusions: The new under fill-function did not work satisfactory. If such function would be more reliable it would be beneficial for the patient controlling hers/his bloodglucose provided that the testing procedure is being correctly done. This is very important because the results are often used to treat the patient.

Abstract Crimean-Congo Hemorrhagic Fever virus (CCHF) and Lassa virus are giving sources illness to humans. In addition to zoonotic transmission, CCHF and Lassa virus can spread from person to person. After a short incubation period, CCHF and Lassa virus infections are characterized by a sudden onset of high fever, chills, headache and cough just like flu. Even some people are vomiting and have diarrhoea. After a few days of illness hemorrhagic manifestations occur. Treatment options for CCHF and Lassa viruses are limited, and there is no vaccine available for use in humans. The purpose of the present study was to produce recombinant nucleocapsid protein of Lassavirus and CCHF virus including an aminoterminal His-tag by a Semliki Forest Virus Replicon (pSFV 4.2). The recombinant proteins are planned to be used in future development of diagnostic methods.

Coeliac disease is a chronic inflammatory disease treated with a gluten-free diet, excluding barley, rye and wheat. Hence, there is a demand for methods able to detect gluten in foods in order to ensure correct labeling of products. According to the Codex Alimentarius Commission, 20ppm gluten is the maximum amount allowed in food labeled gluten-free. PCR can detect DNA from cereals in food. Four real-time PCR-systems, using TaqMan®-probes for detection of barley, oat, rye and wheat were optimized and evaluated. Evaluations were carried out using seeds. Primers were targeted to genes coding for prolamines, seed storage proteins. PCR-systems targeted to barley, oat and wheat were shown to be specific for the cereals corresponding to each system. The system targeted to rye showed cross-reactions with durum wheat and spelt wheat. Detection limits were 50pg, corresponding to &lt;10 haploid genome copies for each cereal. All systems were able to detect 250ppm amounts of DNA, most likely even smaller amounts are detectable. All systems showed an amplification efficiency of ≥95%. Systems for detection of barley, oat and wheat are ready for further evaluation, using food products as samples. The rye system however, needs to be re-designed before further evaluation can take place.

MENEZES, Patrick Lourenço. Erros pré-analíticos em medicina laboratorial: uma revisão sistemática. 2013. 98 f. Dissertação (Mestrado em Saúde, Medicina Laboratorial e Tecnologia Forense) - Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2013. A relevância evidente dos erros pré-analíticos como problema de saúde pública fica patente tanto no dano potencial aos pacientes quanto nos custos ao sistema de saúde, ambos desnecessários e evitáveis. Alguns estudos apontam que a fase pré-analítica é a mais vulnerável a erros, sendo responsável por, aproximadamente, 60 a 90% dos erros laboratoriais em consequência da falta orientação aos pacientes sobre os procedimentos que serão realizados no laboratório clínico. Objetivos: Sistematizar as evidências científicas relacionadas aos erros pré-analíticos dos exames laboratoriais de análises clínicas. Método: Uma revisão sistemática foi realizada, buscando as bases de dados do Medical Literature Analysis and Retrieval System Online (MEDLINE), Scopus(que inclui MEDLINE e Embase), ISI Web of Knowledge, SciFinder, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) (que inclui a Scientific Electronic Library Online SciELO) e o Índice Bibliográfico Espanhol de Ciências de Saúde (IBECS), para artigos publicados entre janeiro de 1990 e junho de 2012 sobre erros de exames laboratoriais que possam ocorrer na fase pré-analítica. Os estudos foram incluídos de acordo com os seguintes exames laboratoriais: hemograma, análise bioquímica do sangue total ou do soro, exames de coagulação sanguínea,uroanálise e exames hematológicos ou bioquímicos em outros materiais e categorizados pelo tipo de erro pré-analítico e pela frequência dos incidentes. Resultados: A busca nas bases de dados bibliográficas resultou no seguinte número de artigos recuperados: 547 na MEDLINE, 229 na Scopus, 110 na ISI, 163 na SciFinder, 228 na Lilacs e 64 na IBECS, perfazendo um total de 1.341 títulos. Ao fim da revisão sistemática, obteve-se um conjunto de 83 artigos para leitura de texto completo, dos quais 14 foram incluídos na revisão. Os estudos abrangeram diferentes tipos de laboratórios, setores técnicos e origem de erros, segundo a fase do processo laboratorial. Discussão: Sete artigos demonstraram erros de pedidos médicos, com uma alta variabilidade nos valores de incidência. Os seis artigos que estudaram erros de coleta de amostra observaram redução deste desfecho. As proporções de eventos adversos relatados e os impactos clínicos variaram, levando a consequências descritas como: erros decorrentes da flebotomia, recoleta de amostras, repetições de exames, atrasos na liberação de resultados de exames e possíveis danos ao paciente. Conclusões: O laboratório deve ter instruções por escrito para cada teste, que descreva o tipo de amostra e procedimento de coleta de amostra. Meios de identificação por código de barras, sistemas robóticos e analíticos reduzem os erros pré-analíticos. A melhoria da fase pré-analítica de testes laboratoriais permanece um desafio para muitos laboratórios clínicos. / The obvious relevance of preanalytical errors as a public health problem is clear in both the potential harm to patients and cost to the health system, both unnecessary and avoidable. Some studies indicate that the pre-analytical phase is the most vulnerable to errors, accounting for approximately 60-90% of laboratory errors as a result of lack guidance to patients about the procedures to be performed in the clinical laboratory. Objectives: To systematize the scientific evidence related to preanalytical errors of clinical analysis laboratory. Method: A systematic review was conducted, searching the databases of the Medical Literature Analysis and Retrieval System Online (MEDLINE) , Scopus (which includes MEDLINE and Embase ), ISI Web of Knowledge , SciFinder , Latin American and Caribbean Health Sciences (LILACS) ( which includes the Scientific Electronic Library Online - SciELO) and the Spanish Bibliographic Index of Health Sciences (IBECS) for articles published between January 1990 and June 2012 on laboratory errors that may occur in the preanalytical phase. Studies were included according to the following laboratory tests: complete blood count, biochemical analysis of whole blood or serum, blood coagulation tests, urinalysis and hematological or biochemical analysis of other materials categorized by the type of pre - analytical error and the frequency of incidents. Results: The search in bibliographic databases resulted in the following number of items retrieved: 547 in MEDLINE, Scopus at 229, 110 in the ISI in SciFinder 163, 228 and 64 in the Lilacs IBECS, a total of 1.341 titles. At the end of the systematic review, we obtained a set of 83 articles for reading the full text, of which 14 were included in the review. The studies covered different types of laboratories, technical sectors and source of errors, according to the phase of the laboratory process. Discussion: Seven articles showed errors in the medical requisition, with a high variability in the incidence values. The six articles that studied sample collection errors observed reduction in this outcome. The proportions of reported adverse events and clinical impacts varied, leading to consequences described as: errors resulting from phlebotomy, recollection of samples, repetition of exams, delays in the release of the test results and possible harm to the patient. Conclusions: The laboratory must have written instructions for each test, which describes the type of sample and collection procedure. Identification methods by barcode, robotic and analytical systems, reduce preanalytical errors. The improvement of pre-analytical phase of laboratory tests remains a challenge for many clinical laboratories.

MENEZES, Patrick Lourenço. Erros pré-analíticos em medicina laboratorial: uma revisão sistemática. 2013. 98 f. Dissertação (Mestrado em Saúde, Medicina Laboratorial e Tecnologia Forense) - Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2013. A relevância evidente dos erros pré-analíticos como problema de saúde pública fica patente tanto no dano potencial aos pacientes quanto nos custos ao sistema de saúde, ambos desnecessários e evitáveis. Alguns estudos apontam que a fase pré-analítica é a mais vulnerável a erros, sendo responsável por, aproximadamente, 60 a 90% dos erros laboratoriais em consequência da falta orientação aos pacientes sobre os procedimentos que serão realizados no laboratório clínico. Objetivos: Sistematizar as evidências científicas relacionadas aos erros pré-analíticos dos exames laboratoriais de análises clínicas. Método: Uma revisão sistemática foi realizada, buscando as bases de dados do Medical Literature Analysis and Retrieval System Online (MEDLINE), Scopus(que inclui MEDLINE e Embase), ISI Web of Knowledge, SciFinder, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) (que inclui a Scientific Electronic Library Online SciELO) e o Índice Bibliográfico Espanhol de Ciências de Saúde (IBECS), para artigos publicados entre janeiro de 1990 e junho de 2012 sobre erros de exames laboratoriais que possam ocorrer na fase pré-analítica. Os estudos foram incluídos de acordo com os seguintes exames laboratoriais: hemograma, análise bioquímica do sangue total ou do soro, exames de coagulação sanguínea,uroanálise e exames hematológicos ou bioquímicos em outros materiais e categorizados pelo tipo de erro pré-analítico e pela frequência dos incidentes. Resultados: A busca nas bases de dados bibliográficas resultou no seguinte número de artigos recuperados: 547 na MEDLINE, 229 na Scopus, 110 na ISI, 163 na SciFinder, 228 na Lilacs e 64 na IBECS, perfazendo um total de 1.341 títulos. Ao fim da revisão sistemática, obteve-se um conjunto de 83 artigos para leitura de texto completo, dos quais 14 foram incluídos na revisão. Os estudos abrangeram diferentes tipos de laboratórios, setores técnicos e origem de erros, segundo a fase do processo laboratorial. Discussão: Sete artigos demonstraram erros de pedidos médicos, com uma alta variabilidade nos valores de incidência. Os seis artigos que estudaram erros de coleta de amostra observaram redução deste desfecho. As proporções de eventos adversos relatados e os impactos clínicos variaram, levando a consequências descritas como: erros decorrentes da flebotomia, recoleta de amostras, repetições de exames, atrasos na liberação de resultados de exames e possíveis danos ao paciente. Conclusões: O laboratório deve ter instruções por escrito para cada teste, que descreva o tipo de amostra e procedimento de coleta de amostra. Meios de identificação por código de barras, sistemas robóticos e analíticos reduzem os erros pré-analíticos. A melhoria da fase pré-analítica de testes laboratoriais permanece um desafio para muitos laboratórios clínicos. / The obvious relevance of preanalytical errors as a public health problem is clear in both the potential harm to patients and cost to the health system, both unnecessary and avoidable. Some studies indicate that the pre-analytical phase is the most vulnerable to errors, accounting for approximately 60-90% of laboratory errors as a result of lack guidance to patients about the procedures to be performed in the clinical laboratory. Objectives: To systematize the scientific evidence related to preanalytical errors of clinical analysis laboratory. Method: A systematic review was conducted, searching the databases of the Medical Literature Analysis and Retrieval System Online (MEDLINE) , Scopus (which includes MEDLINE and Embase ), ISI Web of Knowledge , SciFinder , Latin American and Caribbean Health Sciences (LILACS) ( which includes the Scientific Electronic Library Online - SciELO) and the Spanish Bibliographic Index of Health Sciences (IBECS) for articles published between January 1990 and June 2012 on laboratory errors that may occur in the preanalytical phase. Studies were included according to the following laboratory tests: complete blood count, biochemical analysis of whole blood or serum, blood coagulation tests, urinalysis and hematological or biochemical analysis of other materials categorized by the type of pre - analytical error and the frequency of incidents. Results: The search in bibliographic databases resulted in the following number of items retrieved: 547 in MEDLINE, Scopus at 229, 110 in the ISI in SciFinder 163, 228 and 64 in the Lilacs IBECS, a total of 1.341 titles. At the end of the systematic review, we obtained a set of 83 articles for reading the full text, of which 14 were included in the review. The studies covered different types of laboratories, technical sectors and source of errors, according to the phase of the laboratory process. Discussion: Seven articles showed errors in the medical requisition, with a high variability in the incidence values. The six articles that studied sample collection errors observed reduction in this outcome. The proportions of reported adverse events and clinical impacts varied, leading to consequences described as: errors resulting from phlebotomy, recollection of samples, repetition of exams, delays in the release of the test results and possible harm to the patient. Conclusions: The laboratory must have written instructions for each test, which describes the type of sample and collection procedure. Identification methods by barcode, robotic and analytical systems, reduce preanalytical errors. The improvement of pre-analytical phase of laboratory tests remains a challenge for many clinical laboratories.

One-lung ventilation (OLV) as an established procedure during thoracic surgery may be injurious in terms of increased mechanical stress characterised by alveolar cell stretch and overdistension, increased cyclic tidal recruitment of alveolar units, compression of alveolar vessels and increased pulmonary vascular resistance. This may result in ventilation-induced lung injury with pro-inflammatory cytokine production, leukocyte recruitment and neutrophil-dependent tissue destruction. Despite the consequences of delivering the whole tidal volume (VT) to only a single lung, relatively high VT are used during OLV to maintain arterial oxygenation and carbon dioxide elimination. However, this may increase mechanical stress in the dependent lung and may aggravate alveolar injury. There is a lack of data on the alveolar immune consequences of OLV. Therefore, the present studies investigate the epithelial damage and pro-inflammatory response induced by mechanical ventilation and OLV. OLV induced pulmonary injury, but alveolar damage in the ventilated lung decreased by reduction of the tidal volume in patients scheduled for thoracic surgery (study I). The use of the volatile anaesthetic desflurane in OLV patients attenuated the OLV-induced alveolar immune response (study II). Furthermore, an experimental model of thoracic surgery was established to investigate the systemic and pulmonary consequences of OLV and thoracic surgery in comparison with the effects of conventional two-lung ventilation and spontaneous breathing. The experimental data indicate that beside the pulmonary immune response volatile anaesthetics have also modulated the plasma concentrations of cytokines during and after OLV (study III). In contrast, OLV and thoracic surgery increased the expression of pro-inflammatory mRNA in BAL cells and lung tissue samples. General anaesthesia did not affect this response (study 4). The results of the present studies indicate that OLV and thoracic surgery may be injurious to the lung tissue to a similar degree. The recruitment and activation of alveolar granulocytes characterise the alveolar damage. The administration of different anaesthetics modulates the activation of alveolar cells, specified by decreased inflammatory mediator release in subjects that receive desflurane anaesthesia, which does not affect the expression of cytokine mRNA in alveolar cells and lung tissue samples.

The clinical course of chronic lymphocytic leukemia (CLL) is highly heterogeneous, which has prompted the search for biomarkers that can predict prognosis in this disease. The IGHV gene mutation status and certain genomic aberrations have been identified as reliable prognostic markers of clinical outcome for this disorder. However, the search for more feasible prognostic markers in CLL is still being pursued. Recently, certain single nucleotide polymorphisms (SNPs) in the GNAS1, BCL2 and MDM2 genes and the RNA expression levels of the LPL, ZAP70, TCL1, CLLU1 and MCL1 genes were suggested as novel prognostic markers in CLL. In papers I-III, we performed genotyping analyses of the GNAS1 T393C, BCL2 -938C&gt;A and MDM2 SNP309 polymorphisms in 268-418 CLL patients and related the genotypes with clinical data. Association studies between the polymorphisms and established prognostic markers (i.e. IGHV mutation status, genomic aberrations, CD38 expression) were also performed. Our studies did not find any significant relationship between these SNPs with either clinical outcome or other known prognostic markers in CLL. In paper IV, we measured the RNA expression levels of LPL, ZAP70, TCL1, CLLU1 and MCL1 in 252 CLL cases and correlated these levels with clinical outcome. Here, we verified that high expression of all these RNA-based markers, except MCL1, were associated with an unfavourable prognosis. We also confirmed a close relationship between IGHV mutation status and the RNA-based markers, especially for LPL and CLLU1 expression. Among the RNA-based markers, multivariate analysis revealed LPL expression as the strongest independent prognostic marker for overall survival and time to treatment. Furthermore, the RNA-based markers could add further prognostic information to established markers in subgroups of patients, with LPL expression status giving the most significant results. In summary, data from papers I-III could not verify the GNAS1 T393C, BCL2 -938C&gt;A and MDM2 SNP309 polymorphisms as prognostic markers in CLL. Future SNP markers must hence be confirmed in large, independent cohorts before being proposed as prognostic marker in CLL. In paper IV, we conclude that LPL expression appears to be the strongest among the RNA-based markers for CLL prognostication. Further efforts to standardize LPL quantification are required before it can be applied in the clinical laboratory to predict clinical outcome in this disease.